Context Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CONTEXT THERAPEUTICS INC. | ||
| By: | /s/ Martin Lehr | |
| Martin Lehr | ||
| March 21, 2024 | Chief Executive Officer | |
|---|---|---|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Martin Lehr | Chief Executive Officer and Director (Principal Executive Officer) | March 21, 2024 |
| Martin Lehr | ||
| /s/ Jennifer Minai-Azary | Chief Financial Officer(Principal Financial and Accounting Officer) | March 21, 2024 |
| Jennifer Minai-Azary | ||
| /s/ Richard Berman | Chairman of the Board and Director | March 21, 2024 |
| Richard Berman | ||
| /s/ Philip Kantoff | Director | March 21, 2024 |
| Philip Kantoff | ||
| /s/ Jennifer Evans Stacey | Director | March 21, 2024 |
| Jennifer Evans Stacey | ||
| /s/ Linda West | Director | March 21, 2024 |
| Linda West | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.